[{"data":1,"prerenderedAt":114},["ShallowReactive",2],{"topic-depression-anxiety":3},{"articles":4,"guides":113},[5],{"id":6,"title":7,"author":8,"authorTitle":9,"body":10,"date":99,"description":100,"draft":101,"extension":102,"featured":101,"heroCredit":103,"heroImage":104,"meta":105,"navigation":106,"path":107,"readingTime":108,"seo":109,"stem":110,"topic":111,"__hash__":112},"articles\u002Farticles\u002Ftreatment-resistant-doesnt-mean-person-resistant.md","\"Treatment-resistant\" doesn't mean person-resistant","Higher Place editors",null,{"type":11,"value":12,"toc":90},"minimark",[13,17,22,25,31,35,38,41,45,58,61,65,85],[14,15,16],"p",{},"\"Treatment-resistant depression\" is one of the most consequential phrases in\npsychiatry, and one of the most misread. In research it usually means something\nquite specific: a person has completed at least two adequate courses of\nantidepressant treatment, at a proper dose and for a proper length of time,\nwithout enough improvement. It is a description of what has been tried. It is\nnot a verdict on the person, and the grammar matters.",[18,19,21],"h2",{"id":20},"a-description-of-medicines-not-of-patients","A description of medicines, not of patients",[14,23,24],{},"The resistance lives in the relationship between an illness and the tools\ncurrently available for it — not in some quality of the patient. People who\ncarry the label have usually done everything asked of them, often for years.\nParticipants in the recent Phase 3 psilocybin trials, for example, had been in\ntheir current depressive episode for more than three years on average and had\nlived through more than six episodes over their lives. Hearing \"resistant\" as a\npersonal failing is both inaccurate and, clinically, harmful: it adds shame to\nan illness that already manufactures it.",[26,27,28],"blockquote",{},[14,29,30],{},"The honest version of the term is: \"we have not yet found the thing that\nhelps you.\" That sentence keeps the door open.",[18,32,34],{"id":33},"why-this-is-the-population-in-the-trials","Why this is the population in the trials",[14,36,37],{},"Much psychedelic research recruits exactly these patients, for two reasons.\nOne is ethical: it is easier to justify an experimental treatment with unusual\nrisks for people whose standard options have run out. The other is practical:\nregulators are more willing to consider a new drug for a condition where\nnothing else has worked.",[14,39,40],{},"That should shape how the results are read. In the largest Phase 2 study, about\na third of people who received the higher dose met the definition of response\nat three weeks, and about a fifth were still responding at twelve weeks. In the\nPhase 3 trials that followed, the average benefit over comparison groups was a\nfew points on a depression scale. For a group with this history, that is\nmeaningful. It is also early, partial, and not the same as a cure. A treatment\ncan be a real improvement on \"nothing left to try\" while still helping a\nminority of the people who receive it.",[18,42,44],{"id":43},"what-it-asks-of-clinicians","What it asks of clinicians",[46,47,48,52,55],"ul",{},[49,50,51],"li",{},"Treat the label as a prompt to keep looking, not a place to stop.",[49,53,54],{},"Be honest about uncertainty without communicating hopelessness.",[49,56,57],{},"Remember that the person has likely heard \"resistant\" as \"difficult\" — and\ncorrect that, explicitly.",[14,59,60],{},"The people these studies are built around are not hard cases. They are people\nfor whom the usual map ran out, who are still walking anyway.",[18,62,64],{"id":63},"sources-and-further-reading","Sources and further reading",[46,66,67,75,82],{},[49,68,69,70,74],{},"Gaynes BN et al. \"Defining treatment-resistant depression.\" ",[71,72,73],"em",{},"Depression and\nAnxiety",", 2020.",[49,76,77,78,81],{},"Goodwin GM et al. \"Single-dose psilocybin for a treatment-resistant episode of\nmajor depression.\" ",[71,79,80],{},"New England Journal of Medicine",", 2022.",[49,83,84],{},"Compass Pathways, COMP005 and COMP006 Phase 3 announcements, 2025–2026.",[14,86,87],{},[71,88,89],{},"This essay is general information, not medical advice.",{"title":91,"searchDepth":92,"depth":92,"links":93},"",3,[94,96,97,98],{"id":20,"depth":95,"text":21},2,{"id":33,"depth":95,"text":34},{"id":43,"depth":95,"text":44},{"id":63,"depth":95,"text":64},"2026-04-19","The clinical label describes what medicines have failed to do, not what a person is. That distinction changes how we read the research — and how we treat the people in it.",false,"md","Higher Place — original artwork","\u002Fimg\u002Fheroes\u002Fdepression-anxiety.svg",{},true,"\u002Farticles\u002Ftreatment-resistant-doesnt-mean-person-resistant",6,{"title":7,"description":100},"articles\u002Ftreatment-resistant-doesnt-mean-person-resistant","depression-anxiety","m3cdaXU-SZOvSEK5BxkBtLAubpqJBYwV5--b2wxdpBI",[],1791062476983]